Sugi Predict

Sugi Predict / Compounds / SCHEMBL1499019

SCHEMBL1499019

SCHEMBL1499019

C[Si](C)(C)CCOCn1ccc2c(-c3cnn(C(CC#N)CN4CCN(C(=O)O)CC4)c3)ncnc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 4/20 0.46
▸ TYRO3 Q06418 3/20 0.46
▸ MERTK Q12866 3/20 0.46
▸ JAK2 O60674 9/20 0.37
▸ JAK1 P23458 6/20 0.37
▸ JAK3 P52333 3/20 0.35
▸ TYK2 P29597 2/20 0.35
▸ DAPK3 O43293 2/20 0.34
▸ PAK4 O96013 2/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ RET P07949 2/20 0.34
▸ LTK P29376 2/20 0.34
▸ CSNK1A1 P48729 2/20 0.34
▸ CLK2 P49760 2/20 0.34
▸ TNK2 Q07912 2/20 0.34
▸ ROCK1 Q13464 2/20 0.34
▸ DYRK1A Q13627 2/20 0.34
▸ IKBKE Q14164 2/20 0.34
▸ NTRK3 Q16288 2/20 0.34
▸ NTRK2 Q16620 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1498925 0.91 TYRO3 (0.44) AXLTYRO3MERTKJAK2JAK1
SCHEMBL30100141 0.91 TYRO3 (0.44) AXLTYRO3MERTKJAK2JAK1
SCHEMBL1498852 0.91 TYRO3 (0.44) AXLTYRO3MERTKJAK2JAK1
SCHEMBL1498931 0.91 TYRO3 (0.38) AXLTYRO3MERTKSIGMAR1TPH1
SCHEMBL17467698 0.90 TYRO3 (0.39) AXLTYRO3MERTKJAK2JAK1
SCHEMBL17467700 0.90 TYRO3 (0.39) AXLTYRO3MERTKJAK2JAK1
SCHEMBL6129028 0.89 TYRO3 (0.40) AXLTYRO3MERTKJAK2JAK1
SCHEMBL1498942 0.89 TYRO3 (0.42) AXLTYRO3MERTKJAK2JAK1
SCHEMBL1498950 0.89 JAK2 (0.37) AXLTYRO3MERTKJAK2JAK1
SCHEMBL23067743 0.89 AXL (0.46) AXLTYRO3MERTKTPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2021-03-11 — — US disclosed
US-20190111058-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2019-04-18 — — US disclosed
EP-3110409-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES Incyte Corporation (US) 2017-01-04 — — EP disclosed
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 — — US disclosed
WO-2015131031-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION (US) 2015-09-03 — — WO disclosed
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES INCYTE CORPORATION 2015-09-03 — — US disclosed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 — — WO disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190111058-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885MERTK 447/4885
US-20150246046-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885MERTK 447/4885
US-20210069193-A1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES JAK1, JAK2, JAK3 AXL 1052/4885TYRO3 284/4885MERTK 447/4885
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 AXL 296/4885TYRO3 107/4885MERTK 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.